癌症与微生物组:从关联到干预
本综述总结肠道微生物组作为系统抗癌治疗疗效与毒性可调节决定因素的最新证据,最成熟数据来自免疫检查点抑制剂(ICI)治疗患者。黑色素瘤、非小细胞肺癌和肾细胞癌中,微生物多样性高、生态稳定及免疫刺激通路富集与ICI应答和生存改善相关;抗生素和质子泵抑制剂因破坏微生物组与较差结局相关。微生物组导向干预(粪菌移植、饮食调整、益生菌等)仍处于研究阶段。
要点
- 肠道微生物组组成与功能影响ICI疗效,高多样性及免疫刺激通路富集与更好应答相关。
- 抗生素和质子泵抑制剂破坏微生物组,与ICI治疗较差结局相关。
- 粪菌移植、饮食调整、益生菌等微生物组干预仍在临床研究阶段。
核心结论
- 肠道微生物组是系统抗癌治疗疗效与毒性的可调节决定因素,在ICI治疗中证据最成熟。
研究设计与样本
- 本综述综合肠道微生物组与抗癌治疗结局关联的现有证据,评估治疗性调控策略与挑战,并介绍真菌组新见解。
主要发现
- 在黑色素瘤、非小细胞肺癌和肾细胞癌中,微生物多样性更高、生态稳定性更好及免疫刺激通路富集与ICI应答和生存改善相关。
- 抗生素和质子泵抑制剂因破坏微生物组而与较差结局相关。
- 肠道微生物可通过影响免疫致敏、抗原呈递、宿主-微生物共代谢、药物生物转化和上皮屏障完整性影响治疗结局。
临床怎么用
- 在ICI治疗患者中应关注抗生素和质子泵抑制剂对微生物组的破坏及潜在不良影响。
- 微生物组导向干预(粪菌移植、饮食调整、益生菌等)目前仍属研究性,不宜常规临床推荐。
局限性
- 微生物组导向干预仍处于研究阶段,尚未确立标准方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by affecting immune priming, antigen presentation, host-microbial co-metabolism, drug biotransformation, and epithelial barrier integrity. In melanoma, non-small-cell lung cancer, and renal cell carcinoma, higher microbial diversity, ecological stability, and enrichment of immunostimulatory pathways have been associated with improved ICI response and survival. By contrast, antibiotics and proton pump inhibitors are linked to inferior outcomes because they disrupt the microbiome. Microbiome-directed interventions, including faecal microbiota transplantation, dietary modifications, prebiotics, probiotics, and live biotherapeutic products, are undergoing clinical testing but remain at the investigational stage. This Review synthesises current evidence linking the intestinal microbiome to anticancer therapy outcomes, evaluates strategies and challenges for therapeutic modulation of the microbiome, and introduces emerging insights into the mycobiome.
引用
- Moradi A, Winayak R, Pal SK, et al. Cancer and the microbiome: from association to intervention. Lancet Oncol. 2026. PMID: 42805210. doi:10.1016/S1470-2045(26)00326-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。